Live tape
Top 8, mentions 7d16,061NVDA4,677 mentions▲ +0.04GOOGL2,642 mentions▲ +0.04AMD1,977 mentions▲ +0.08SPY1,799 mentions▲ +0.06QQQ1,715 mentions▲ +0.06SPCX1,166 mentions▲ +0.05TSLA1,053 mentions▲ +0.05AAPL1,032 mentions▲ +0.05

Equity · Healthcare

ORMP

NASDAQ

Oramed Pharmaceuticals (ORMP)

4 USD −2.91% vs prior close Nov 2, 2026
Oramed Pharmaceuticals Inc. price graph
48 sessions
5.5 3.5 11 Aug 2 Nov

The line runs 4.27 USD on 11 August through 4 USD on 2 November, on a scale from 3.5 to 5.5. Days the market did not trade hold the previous close, flat.

Track this symbol on TradingView
Market cap
166.4M USD
P/E (TTM)
1.0
Revenue, year to Dec 2025
2.0M USD
EPS, diluted, year to Dec 2025
1.50 USD
52-week range
2.21 USD – 5.35 USD
Avg volume
8.5K

as of Nov 2, 2026

Have Oramed Pharmaceuticals (ORMP) insiders bought or sold shares recently?

In the 90 days to 10 Nov 2026, Oramed Pharmaceuticals insiders reported 2 open-market sales and no purchases (SEC Form 4); the filings we hold, back to 31 Dec 2025, show no open-market purchase.

Form 4, 90 days to 10 Nov 2026, newest reported trade 1 Oct 2026

Buys 0Sells 2Net sold $226KOther filings 4

Have Oramed Pharmaceuticals (ORMP) insiders bought or sold shares recently?
ReportedInsiderTypeSharesValue
01 Oct 2026Gabay AvrahamChief Financial OfficerSell20,00090K USD
01 Oct 2026Hexter JoshuaCOO & CBOSell30,000135K USD
Sold2 open-market sales50,000$226K
4 other filings in the window: grants, exercises, tax withholding and transfers, not trades
Have Oramed Pharmaceuticals (ORMP) insiders bought or sold shares recently?
ReportedInsiderTypeSharesValue
24 Sep 2026KIDRON NADAVPresident and CEOAward718,262
24 Sep 2026Hexter JoshuaCOO & CBOAward284,746
24 Sep 2026Kidron MiriamChief Scientific OfficerAward417,416
24 Sep 2026Gabay AvrahamChief Financial OfficerAward209,291

Which funds hold Oramed Pharmaceuticals (ORMP)?

4 of the 45 institutional funds we track reported a Oramed Pharmaceuticals position for the quarter ended 30 Jun 2026 — a combined 1.7M USD; the latest of those filings landed 02 Sep 2026.

Form 13F

Which funds hold Oramed Pharmaceuticals (ORMP)?
FundPositionSharesValueShares q/q
Renaissance TechnologiesHeld (±25%)183,800884K USD+24.4%
Marshall WaceTrimmed101,953490K USD−60.7%
Citadel AdvisorsTrimmed41,565200K USD−57.9%
Millennium ManagementAdded21,861105K USD+36.5%
Point72 Asset ManagementExited

Have members of Congress traded Oramed Pharmaceuticals (ORMP)?

The most recent congressional trade disclosed in Oramed Pharmaceuticals is a purchase by Andrew R. Garbarino (house, NY), dated 23 Apr 2021.

STOCK Act disclosures

Have members of Congress traded Oramed Pharmaceuticals (ORMP)?
TradedMemberTypeAmountFiled after
23 Apr 2021Andrew R. Garbarinohouse · Republican–NYPurchase1K USD–15K USD31 days

What has been filed or recorded for Oramed Pharmaceuticals (ORMP)?

The filings we hold for Oramed Pharmaceuticals, newest first: 3 fails-to-deliver days, 6 quarterly earnings reports, 2 annual reports and 5 reported financial figures, the latest dated 08 Oct 2026. No next earnings date is announced in SEC filings yet.

What has been filed or recorded for Oramed Pharmaceuticals (ORMP)?
And
08 Oct 2026Fails to deliverShares failed to deliver485 shares2K USD notional · 0.001% of shares out
07 Oct 2026Fails to deliverShares failed to deliver6 shares26 USD notional · <0.001% of shares out
25 Sep 2026Fails to deliverShares failed to deliver2 shares10 USD notional · <0.001% of shares out
30 Jun 2026Quarterly earningsQ2 2026 reportedEPS 1.84 USD
30 Jun 2026FinancialsTotal assets369.6M USDat period end
30 Jun 2026FinancialsTotal equity incl. minority interest317.5M USDat period end
31 Mar 2026Quarterly earningsQ1 2026 reportedEPS 0.91 USD
31 Dec 2025Annual reportFY 2025 reportedEPS 1.50 USDRevenue $2M
31 Dec 2025FinancialsRevenue2.0M USDfiscal year
31 Dec 2025FinancialsNet income64.1M USDfiscal year
31 Dec 2025FinancialsDiluted EPS1.50 USDfiscal year
30 Sep 2025Quarterly earningsQ3 2025 reportedEPS 1.13 USDRevenue $2M
30 Jun 2025Quarterly earningsQ2 2025 reportedEPS 0.31 USDRevenue $2M
31 Mar 2025Quarterly earningsQ1 2025 reportedEPS −0.19 USDRevenue $2M
31 Dec 2024Annual reportFY 2024 reportedEPS −0.48 USD
30 Sep 2024Quarterly earningsQ3 2024 reportedEPS −0.48 USD

Oramed Pharmaceuticals (ORMP): frequently asked questions

From live data
4.00

What did Oramed Pharmaceuticals shares close at?

Oramed Pharmaceuticals closed at 4.00 USD on 2 Nov 2026, down 2.91% on the close before. That is the end-of-day price from Finazon, not a live quote.

166.4M

What is Oramed Pharmaceuticals’ market cap?

Oramed Pharmaceuticals is worth 166.4M USD by market value as of 2 Nov 2026, which is the share price times the shares on issue from its SEC filings.

1.0

What is Oramed Pharmaceuticals’ P/E ratio?

Oramed Pharmaceuticals has a price-to-earnings ratio of 1.0, as of 2 Nov 2026: the share price divided by what the company earned per share over the last four reported quarters. A higher number means the market pays more for each dollar of earnings.

2.0M

What is Oramed Pharmaceuticals’ revenue?

Oramed Pharmaceuticals reported revenue of 2.0M USD for the year ended 31 Dec 2025, as filed with the SEC. See Filings

2 sales

Have Oramed Pharmaceuticals insiders bought or sold shares recently?

In the 90 days to 10 Nov 2026, Oramed Pharmaceuticals insiders reported 2 open-market sales and no purchases (SEC Form 4); the filings we hold, back to 31 Dec 2025, show no open-market purchase. A further 4 filings were grants, awards, gifts or exercises rather than open-market trades. See Insiders

4 of 45

Which funds own Oramed Pharmaceuticals?

4 of the 45 funds we track reported a Oramed Pharmaceuticals position for the quarter ended 30 Jun 2026, per their SEC Form 13F filings. The largest reported positions were Renaissance Technologies, Marshall Wace and Citadel Advisors. See Funds

1 trade

Have members of Congress traded Oramed Pharmaceuticals?

Yes. 1 trade in Oramed Pharmaceuticals appears in the congressional disclosures we hold: a purchase by Andrew R. Garbarino (House, NY) dated 23 Apr 2021, filed 24 May 2021. Amounts are disclosed as ranges, and a filing can follow the trade by up to 45 days. See Congress

1.84

When did Oramed Pharmaceuticals last report earnings?

Oramed Pharmaceuticals last reported earnings on 30 Jun 2026 for Q2 2026, with EPS of 1.84 USD; no next date is announced in SEC filings yet. See Filings

Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.

References
  1. Finazonprior-day close, indicative (IEX-derived, not the official close), some closes dollar-rounded at the source
  2. TradingViewthe price chart widget, drawn by TradingView from their own data
  3. SEC EDGARForm 4 filings (insider transactions)
  4. SEC EDGAR13F filings
  5. House disclosuresU.S. House of Representatives financial disclosures
  6. SECSEC fails-to-deliver (CNS) data
  7. SEC EDGARXBRL company facts, latest period ended 30 Jun 2026
  8. SEC EDGARreported earnings figures and scheduled report dates
  9. SEC EDGARValuation computed from SEC EDGAR filings